Entering text into the input field will update the search result below

Guardant Health on deck for IPO

  • Redwood City, CA-based Guardant Health (NASDAQ:GH) has filed a prospectus for a $100M IPO.
  • The oncology firm provides liquid biopsy molecular diagnostic testing services for cancer. Lead test is Guardant360, a 73-gene panel for advanced-stage cancer.
  • 2018 Financials (6 mo.)($M): Revenue: 36.1 (+93.0%); Net Loss: (35.5) (+10.4%); Cash Consumption: (23.6) (+14.2%).
  • Liquid biopsy-related tickers: TROV, OTCQX:RHHBY, BIOC, OCX, ILMN, TECH, FMI, GHDX, PRPO, OTCPK:MXDHF, ZOMHF, NSTG

Recommended For You

About GH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GH--
Guardant Health, Inc.